Efficacy of LGE-MRI-guided fibrosis ablation versus conventional catheter ablation of atrial fibrillation: The DECAAF II trial: Study design.
Nassir F MarroucheTom GreeneJ Michael DeanEugene G KholmovskiLeonie Morrison-de BoerMoussa MansourHugh CalkinsFrancis E MarchlinskiDavid WilberGerhard HindricksChristian MahnkopfPierre JaisPrashanthan SandersJohannes BrachmannJereon BaxLilas DagherOussama WazniNazem Akoumnull nullPublished in: Journal of cardiovascular electrophysiology (2021)
The DECAAF II trial is the first prospective, randomized, multicenter trial of patients with persistent AF using imaging defined atrial fibrosis as a treatment target. The trial will help define an optimal approach to catheter ablation of persistent AF, further our understanding of influencers of ablation lesion formation, and refine selection criteria for ablation based on atrial myopathy burden.
Keyphrases
- catheter ablation
- atrial fibrillation
- phase iii
- left atrial
- phase ii
- left atrial appendage
- study protocol
- oral anticoagulants
- open label
- clinical trial
- direct oral anticoagulants
- heart failure
- double blind
- placebo controlled
- magnetic resonance imaging
- randomized controlled trial
- coronary artery disease
- left ventricular
- early onset
- magnetic resonance
- computed tomography
- acute coronary syndrome